SecBot SecBot
SECBOTREPLAY Home › Report › PTCT

PTCT · PTC Therapeutics announced a $500 million share repurchase program,…

PTC Therapeutics, Inc. · PRESS-RELEASE filed Nov 3, 2026 at 07:00 ET

At the news

NEUTRALIMPACT 3/10

PRESS-RELEASE filed Nov 3, 2026 at 07:00 ET

PTC Therapeutics announced a $500 million share repurchase program, representing ~9.3% of its $5.4B market cap. The buyback follows strong Q3 2026 results reported 5 days ago, where total revenue of $357.6M beat consensus and full-year product revenue guidance was raised to $960M-$990M.

  • Board authorized up to $500 million in share repurchases
  • Repurchases may be made through open-market transactions, privately negotiated deals, or accelerated share repurchases
  • Authorization represents ~9.3% of current market cap ($5.4B)
  • Follows Q3 2026 earnings beat (revenue $357.6M vs $305.0M consensus) and raised product revenue guidance to $960M-$990M

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access